Telomerase-transduced osteoarthritic fibroblast-like synoviocyte cell line.
Telomerase-transduced osteoarthritic fibroblast-like synoviocyte cell line.
复制标题
端粒酶转导的骨关节炎成纤维细胞样滑膜细胞系。
DOI：
10.1016/j.bbrc.2004.09.005
复制
发表时间：
2004
影响因子：
3.1
通讯作者：
Cheung,HermanS
中科院分区：
文献类型：
--
作者：
Sun,Yubo;Firestein,GaryS;Wenger,Leonor;Huang,Chun-YuhC;Cheung,HermanS
为了检查成纤维细胞样滑膜细胞（FLS）的寿命是否可以延长并建立保留原代FLS特征的FLS细胞系，我们将人端粒酶催化亚基（hTERT）基因引入人骨关节炎（OA）FLS中。建立了两种 hTERT 转导的克隆细胞系，并对一种细胞系 hTERT-OA FLS 13A 进行了表征。 hTERT-OA FLS 13A 细胞具有与亲本未转导细胞相似的形态，并且具有与早期传代的亲本细胞相似的群体倍增时间。虽然亲本未转导的 OA FLS 在培养 100 天后达到衰老，但 hTERT-OA FLS 13A 细胞继续以大约每 2-3 天一次的群体倍增率生长。 hTERT-OA 13A 细胞迄今为止已在培养物中生长超过 450 天，并保持相同的生长速度。此外，hTERT-OA FLS 13A 细胞保留了对碱性磷酸钙晶体和白细胞介素 1β 治疗的敏感性和反应。总之，端粒酶的外源表达代表了延长人类FLS寿命的一种方法，端粒酶转导的FLS细胞为基因调控、基于细胞的测定、基于细胞移植的基因治疗和组织工程研究和开发提供了一种有前途的工具。
To examine whether the life span of fibroblast-like synoviocytes (FLSs) can be extended and to establish FLS cell lines that preserve the characteristics of primary FLSs, we introduced human catalytic subunit of telomerase (hTERT) gene into human osteoarthritic (OA) FLSs. Two hTERT-transduced clonal cell lines were established and one line, hTERT-OA FLS 13A, was characterized. The hTERT-OA FLS 13A cells have a morphology similar to that of the parental untransduced cells and a population-doubling time similar to that of the parental cells of early passages. While the parental untransduced OA FLSs reached senescence after 100 days in culture, the hTERT-OA FLS 13A cells continued to grow at a population-doubling rate of once in about every 2–3 days. The hTERT-OA 13A cells have so far grown in culture beyond 450 days and maintained the same growth rate. Furthermore, the hTERT-OA FLS 13A cells preserved their sensitivity and response to the treatment with basic calcium phosphate crystals and interleukin-1β. In conclusion, exogenous expression of telomerase represents a way to extend the life span of human FLSs and telomerase-transduced FLS cells offer a promising tool for gene regulation, cell-based assay, cell transplantation-based gene therapy, and tissue engineering research and development.